SCHEDULE 13D/A: Hanmi Pharmaceutical Converts Debt to Equity in Aptose Biosciences, Increases Stake to 19.93% Amidst New Capital Raise Plans

Hanmi Pharmaceutical Co., Ltd. has converted $1.51 million of debt into common shares of Aptose Biosciences Inc., increasing its beneficial ownership to 19.93% and securing enhanced investor rights, while Aptose plans a new $15 million capital raise.

Summary

• Hanmi Pharmaceutical Co., Ltd. (the "Reporting Person") has filed an Amendment No. 3 to its Schedule 13D regarding its investment in Aptose Biosciences Inc. (the "Issuer").
• On March 18, 2025, Hanmi and Aptose entered into a Debt Conversion and Interest Payment Agreement and a Second Amended and Restated Investor's Rights Agreement.
• Hanmi converted a portion of its loan to Aptose, specifically $1,513,533.10, into 409,063 common shares at a price of $3.70 per share.
• Following this conversion, Hanmi beneficially owns 508,710 common shares, representing approximately 19.93% of Aptose's outstanding common shares (based on 2,552,429 shares outstanding as of March 18, 2025).
• Hanmi retains 77,972 warrants, which, if fully exercised, would bring its beneficial ownership to 22.30%, though exercise is restricted to maintain ownership below 19.99%.
• Aptose aims to raise an additional $15,000,000 USD (not including the converted amount) through At-the-Market offerings, Committed Equity Facility, and/or private and/or public offerings.
• The Q1 2025 interest payment (for the period December 21, 2024, to March 31, 2025) on the remaining loan amount may be delayed until June 27, 2025, without incurring default interest, contingent on the completion of the capital raise.
• The Second A&R IRA grants Hanmi customary registration rights, informational rights, preemptive rights, and the right to nominate an individual to serve as an employee of Aptose, provided Hanmi maintains at least 10% beneficial ownership.

Sentiment

Score: 6

Explanation: The conversion of debt to equity is a positive step for Aptose's balance sheet and signals continued commitment from a key strategic investor, Hanmi Pharmaceutical. The enhanced investor rights also suggest a deeper, more aligned partnership. However, the company's stated need to raise an additional $15 million and the delayed interest payment indicate persistent capital requirements and potential dilution, balancing the positive aspects of the debt conversion.

Positives

• The conversion of $1,513,533.10 in debt to equity strengthens Aptose's balance sheet by reducing its outstanding loan obligations.
• Hanmi Pharmaceutical's increased beneficial ownership to 19.93% demonstrates continued strategic commitment and confidence in Aptose Biosciences.
• The new Second Amended and Restated Investor's Rights Agreement provides Hanmi with enhanced governance and information rights, including the ability to nominate an employee, suggesting deeper strategic alignment and oversight.
• The provision for potential future conversion of the remaining Indebtedness Amount by Hanmi offers a flexible financing mechanism for Aptose.
• Conditional approval from the Toronto Stock Exchange (TSX) for the listing of the newly issued shares indicates regulatory support for the transaction.

Negatives

• The conversion of debt into equity, while reducing liabilities, results in dilution for existing shareholders.
• The delay in the Q1 2025 interest payment until June 27, 2025, contingent on a capital raise, suggests potential liquidity challenges for Aptose.
• Aptose's stated need to raise an additional $15,000,000 USD indicates ongoing significant capital requirements, which could lead to further shareholder dilution.
• The 19.99% ownership cap on Hanmi's warrant exercise limits its immediate ability to increase its stake further without triggering certain regulatory thresholds or anti-takeover provisions.

Risks

• Aptose's ability to successfully complete the planned $15,000,000 USD capital raise is critical for its financial stability and for avoiding default interest on the Q1 2025 loan interest payment.
• Failure to execute a definitive collaboration agreement by June 30, 2025, could impact the future treatment of the remaining Indebtedness Amount and potential milestone obligations related to Tuspetinib.
• The ongoing need for capital raises could lead to significant dilution for existing shareholders if new shares are issued at lower prices.
• The company's obligation to use the Indebtedness Amount solely for Tuspetinib-related business operations concentrates a significant portion of its funding to a specific drug development program, increasing program-specific risk.

Future Outlook

Aptose Biosciences Inc. plans to file a registration statement on Form S-1 with the SEC to facilitate a capital raise of $15,000,000 USD through various offerings. The company and Hanmi Pharmaceutical Co., Ltd. are also negotiating a definitive collaboration agreement, with a target execution date of June 30, 2025, which could lead to further conversion of the remaining loan balance into prepayment of future milestone obligations. Hanmi also has the option to convert the remaining loan amount into equity after the capital raise, subject to an ownership cap.

Management Comments

• "The Company aims to raise fifteen million United States Dollars (USD) (USD 15,000,000) (the Capital Raise), not including the amount being converted pursuant to this Agreement, through At-the-Market offerings, Committed Equity Facility, and/or private and/or public offerings following the Company's filing of a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (the Commission) or equivalent."
• "The Parties hereby acknowledge and agree that (i) they have engaged in good faith in a negotiation regarding (a) executing the Collaboration by June 30, 2025 and (b) determining the mutually agreeable method of the future treatment of the remaining Indebtedness Amount, including both the principal and the accrued interest thereon."

Industry Context

This transaction reflects a common strategy in the biotechnology and pharmaceutical sectors where strategic investors like Hanmi Pharmaceutical provide financing to drug development companies like Aptose Biosciences, often with provisions for debt-to-equity conversion and collaboration. Such arrangements can provide crucial capital for R&D, particularly for companies focused on specific drug candidates like Tuspetinib. The ongoing need for capital raises is typical for pre-revenue biotech firms, and the structured investment from a larger pharmaceutical company can be seen as a vote of confidence and a potential pathway to future partnerships or commercialization.

Comparison to Industry Standards

• The debt conversion at a fixed price of $3.70 per share is a common mechanism for strategic investors to gain equity exposure while providing capital, similar to structured financing deals seen with other biotech firms like BioNTech or Moderna in their early stages with larger pharmaceutical partners.
• The 19.99% ownership cap for warrant exercise is a standard provision to avoid triggering certain change-of-control clauses or shareholder approval requirements that typically apply at 20% ownership thresholds, a common practice observed in strategic investments across various industries to maintain regulatory compliance and avoid hostile takeover implications.
• The inclusion of customary registration rights, informational rights, and preemptive rights for a significant investor like Hanmi is standard practice, ensuring liquidity and protecting their investment from future dilution, mirroring agreements seen in venture capital or private equity investments in growth-stage companies.
• The right to nominate an employee, particularly in a technical area related to the core business (Tuspetinib), is a strong indicator of a deeper strategic partnership, similar to what is seen in joint ventures or co-development agreements in the biotech space, where the investor seeks direct operational insight and influence, such as the collaboration between Gilead Sciences and Galapagos NV on inflammatory diseases.

Corporate Governance

Related Party Transactions

• Hanmi Pharmaceutical Co., Ltd. (Reporting Person) converted a portion of its loan to Aptose Biosciences Inc. (Issuer) into common shares, a transaction between a significant shareholder/lender and the company.
• The Facility Agreement, Debt Conversion and Interest Payment Agreement, and Second Amended and Restated Investor's Rights Agreement are all direct agreements between Hanmi and Aptose.
• The provision for Hanmi to nominate an employee and for Aptose to perform services for Hanmi (e.g., CRO services, Tuspetinib-related work) under a separate Service Agreement, with expenses borne by Hanmi, constitutes an ongoing related party transaction.

Stakeholder Impact

• Shareholders: Potential for dilution from the planned $15,000,000 USD capital raise. Existing shareholders' ownership percentage will decrease due to the debt-to-equity conversion, but the company's debt burden is reduced. Enhanced investor rights for Hanmi could lead to more stable governance and strategic direction.
• Creditors (Hanmi as a lender): A portion of the loan is converted to equity, reducing Hanmi's debt exposure but increasing its equity risk. The remaining loan interest payment is delayed, indicating some flexibility for the company.
• Employees: The right for Hanmi to nominate an employee could introduce new personnel or strategic direction, potentially impacting existing team dynamics or roles, particularly in technical areas.

Next Steps

• Aptose Biosciences Inc. to file a registration statement on Form S-1 with the SEC for the planned $15,000,000 USD capital raise.
• Aptose and Hanmi Pharmaceutical to continue negotiations for a definitive collaboration agreement, targeting execution by June 30, 2025.
• Aptose to make the Q1 2025 interest payment by June 27, 2025, to avoid default interest, contingent on the capital raise.
• Hanmi Pharmaceutical has the option to convert the remaining Indebtedness Amount into common shares after the capital raise, subject to an ownership cap.
• Aptose to retain an Investor Nominee as an employee, with a separate Service Agreement to be entered into.

Key Dates

Recommendation

Keywords

Aptose Biosciences, Hanmi Pharmaceutical, Debt Conversion, Equity Financing, SEC Filing, Schedule 13D, Investor Rights Agreement, Common Shares, Warrants, Capital Raise, Tuspetinib, Biotechnology, Pharmaceuticals, Corporate Governance, Strategic Investment, Shareholder Dilution